 | • レポートコード：MRC2-11QY04180 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は患者由来異種移植/PDXモデルのグローバル市場について調査・分析したレポートです。種類別（消化管間質腫瘍モデル、婦人科腫瘍モデル、呼吸器腫瘍モデル、泌尿器腫瘍モデル、血液腫瘍モデル）市場規模、用途別（前臨床医薬品開発・基礎がん研究、バイオマーカー分析）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別患者由来異種移植/PDXモデルの競争状況、市場シェア ・世界の患者由来異種移植/PDXモデル市場：種類別市場規模 2015年-2020年（消化管間質腫瘍モデル、婦人科腫瘍モデル、呼吸器腫瘍モデル、泌尿器腫瘍モデル、血液腫瘍モデル） ・世界の患者由来異種移植/PDXモデル市場：種類別市場規模予測 2021年-2026年（消化管間質腫瘍モデル、婦人科腫瘍モデル、呼吸器腫瘍モデル、泌尿器腫瘍モデル、血液腫瘍モデル） ・世界の患者由来異種移植/PDXモデル市場：用途別市場規模 2015年-2020年（前臨床医薬品開発・基礎がん研究、バイオマーカー分析） ・世界の患者由来異種移植/PDXモデル市場：用途別市場規模予測 2021年-2026年（前臨床医薬品開発・基礎がん研究、バイオマーカー分析） ・北米の患者由来異種移植/PDXモデル市場分析：米国、カナダ ・ヨーロッパの患者由来異種移植/PDXモデル市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの患者由来異種移植/PDXモデル市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の患者由来異種移植/PDXモデル市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの患者由来異種移植/PDXモデル市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Crown Bioscience、The Jackson Laboratory、Champions Oncology、Charles River Laboratories、WuXi Apptec、Oncodesign、Horizon Discovery、Pharmatest Services、Hera Biolabs、EPO Berlin-Buch、Xentech、Urolead ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. PDX models are used to create an environment that allows for the natural growth of cancer, its monitoring, and corresponding treatment evaluations for the original patient.
Several types of immunodeficient mice can be used to establish PDX models: athymic nude mice, severely compromised immune deficient (SCID) mice, NOD-SCID mice, and recombination-activating gene 2 (Rag2)-knockout mice. The mice used must be immunocompromised to prevent transplant rejection. The NOD-SCID mouse is considered more immunodeficient than the nude mouse, and therefore is more commonly used for PDX models because the NOD-SCID mouse does not produce natural killer cells.
Market Analysis and Insights: Global Patient Derived Xenograft/PDX Models Market
The global Patient Derived Xenograft/PDX Models market size is projected to reach US$ 95 million by 2026, from US$ 86 million in 2020, at a CAGR of 9.5%% during 2021-2026.
Global Patient Derived Xenograft/PDX Models Scope and Market Size
Patient Derived Xenograft/PDX Models market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Patient Derived Xenograft/PDX Models market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Crown Bioscience
The Jackson Laboratory
Champions Oncology
Charles River Laboratories
WuXi Apptec
Oncodesign
Horizon Discovery
Pharmatest Services
Hera Biolabs
EPO Berlin-Buch
Xentech
Urolead
Market segment by Type, the product can be split into
Gastrointestinal Tumor Models
Gynecological Tumor Models
Respiratory Tumor Models
Urological Tumor Models
Hematological Tumor Models
Market segment by Application, split into
Pre-clinical Drug Development and Basic Cancer Research
Biomarker Analysis
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Patient Derived Xenograft/PDX Models Revenue
1.4 Market by Type
1.4.1 Global Patient Derived Xenograft/PDX Models Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Gastrointestinal Tumor Models
1.4.3 Gynecological Tumor Models
1.4.4 Respiratory Tumor Models
1.4.5 Urological Tumor Models
1.4.6 Hematological Tumor Models
1.5 Market by Application
1.5.1 Global Patient Derived Xenograft/PDX Models Market Share by Application: 2020 VS 2026
1.5.2 Pre-clinical Drug Development and Basic Cancer Research
1.5.3 Biomarker Analysis
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Patient Derived Xenograft/PDX Models Market Perspective (2015-2026)
2.2 Global Patient Derived Xenograft/PDX Models Growth Trends by Regions
2.2.1 Patient Derived Xenograft/PDX Models Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Patient Derived Xenograft/PDX Models Historic Market Share by Regions (2015-2020)
2.2.3 Patient Derived Xenograft/PDX Models Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Patient Derived Xenograft/PDX Models Market Growth Strategy
2.3.6 Primary Interviews with Key Patient Derived Xenograft/PDX Models Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Patient Derived Xenograft/PDX Models Players by Market Size
3.1.1 Global Top Patient Derived Xenograft/PDX Models Players by Revenue (2015-2020)
3.1.2 Global Patient Derived Xenograft/PDX Models Revenue Market Share by Players (2015-2020)
3.1.3 Global Patient Derived Xenograft/PDX Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Patient Derived Xenograft/PDX Models Market Concentration Ratio
3.2.1 Global Patient Derived Xenograft/PDX Models Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Patient Derived Xenograft/PDX Models Revenue in 2019
3.3 Patient Derived Xenograft/PDX Models Key Players Head office and Area Served
3.4 Key Players Patient Derived Xenograft/PDX Models Product Solution and Service
3.5 Date of Enter into Patient Derived Xenograft/PDX Models Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Patient Derived Xenograft/PDX Models Historic Market Size by Type (2015-2020)
4.2 Global Patient Derived Xenograft/PDX Models Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
5.2 Global Patient Derived Xenograft/PDX Models Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Patient Derived Xenograft/PDX Models Market Size (2015-2020)
6.2 Patient Derived Xenograft/PDX Models Key Players in North America (2019-2020)
6.3 North America Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
6.4 North America Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
7 Europe
7.1 Europe Patient Derived Xenograft/PDX Models Market Size (2015-2020)
7.2 Patient Derived Xenograft/PDX Models Key Players in Europe (2019-2020)
7.3 Europe Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
7.4 Europe Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
8 China
8.1 China Patient Derived Xenograft/PDX Models Market Size (2015-2020)
8.2 Patient Derived Xenograft/PDX Models Key Players in China (2019-2020)
8.3 China Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
8.4 China Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
9 Japan
9.1 Japan Patient Derived Xenograft/PDX Models Market Size (2015-2020)
9.2 Patient Derived Xenograft/PDX Models Key Players in Japan (2019-2020)
9.3 Japan Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
9.4 Japan Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Patient Derived Xenograft/PDX Models Market Size (2015-2020)
10.2 Patient Derived Xenograft/PDX Models Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
10.4 Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
11 India
11.1 India Patient Derived Xenograft/PDX Models Market Size (2015-2020)
11.2 Patient Derived Xenograft/PDX Models Key Players in India (2019-2020)
11.3 India Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
11.4 India Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Patient Derived Xenograft/PDX Models Market Size (2015-2020)
12.2 Patient Derived Xenograft/PDX Models Key Players in Central & South America (2019-2020)
12.3 Central & South America Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
12.4 Central & South America Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Crown Bioscience
13.1.1 Crown Bioscience Company Details
13.1.2 Crown Bioscience Business Overview
13.1.3 Crown Bioscience Patient Derived Xenograft/PDX Models Introduction
13.1.4 Crown Bioscience Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020))
13.1.5 Crown Bioscience Recent Development
13.2 The Jackson Laboratory
13.2.1 The Jackson Laboratory Company Details
13.2.2 The Jackson Laboratory Business Overview
13.2.3 The Jackson Laboratory Patient Derived Xenograft/PDX Models Introduction
13.2.4 The Jackson Laboratory Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.2.5 The Jackson Laboratory Recent Development
13.3 Champions Oncology
13.3.1 Champions Oncology Company Details
13.3.2 Champions Oncology Business Overview
13.3.3 Champions Oncology Patient Derived Xenograft/PDX Models Introduction
13.3.4 Champions Oncology Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.3.5 Champions Oncology Recent Development
13.4 Charles River Laboratories
13.4.1 Charles River Laboratories Company Details
13.4.2 Charles River Laboratories Business Overview
13.4.3 Charles River Laboratories Patient Derived Xenograft/PDX Models Introduction
13.4.4 Charles River Laboratories Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.4.5 Charles River Laboratories Recent Development
13.5 WuXi Apptec
13.5.1 WuXi Apptec Company Details
13.5.2 WuXi Apptec Business Overview
13.5.3 WuXi Apptec Patient Derived Xenograft/PDX Models Introduction
13.5.4 WuXi Apptec Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.5.5 WuXi Apptec Recent Development
13.6 Oncodesign
13.6.1 Oncodesign Company Details
13.6.2 Oncodesign Business Overview
13.6.3 Oncodesign Patient Derived Xenograft/PDX Models Introduction
13.6.4 Oncodesign Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.6.5 Oncodesign Recent Development
13.7 Horizon Discovery
13.7.1 Horizon Discovery Company Details
13.7.2 Horizon Discovery Business Overview
13.7.3 Horizon Discovery Patient Derived Xenograft/PDX Models Introduction
13.7.4 Horizon Discovery Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.7.5 Horizon Discovery Recent Development
13.8 Pharmatest Services
13.8.1 Pharmatest Services Company Details
13.8.2 Pharmatest Services Business Overview
13.8.3 Pharmatest Services Patient Derived Xenograft/PDX Models Introduction
13.8.4 Pharmatest Services Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.8.5 Pharmatest Services Recent Development
13.9 Hera Biolabs
13.9.1 Hera Biolabs Company Details
13.9.2 Hera Biolabs Business Overview
13.9.3 Hera Biolabs Patient Derived Xenograft/PDX Models Introduction
13.9.4 Hera Biolabs Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.9.5 Hera Biolabs Recent Development
13.10 EPO Berlin-Buch
13.10.1 EPO Berlin-Buch Company Details
13.10.2 EPO Berlin-Buch Business Overview
13.10.3 EPO Berlin-Buch Patient Derived Xenograft/PDX Models Introduction
13.10.4 EPO Berlin-Buch Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
13.10.5 EPO Berlin-Buch Recent Development
13.11 Xentech
10.11.1 Xentech Company Details
10.11.2 Xentech Business Overview
10.11.3 Xentech Patient Derived Xenograft/PDX Models Introduction
10.11.4 Xentech Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
10.11.5 Xentech Recent Development
13.12 Urolead
10.12.1 Urolead Company Details
10.12.2 Urolead Business Overview
10.12.3 Urolead Patient Derived Xenograft/PDX Models Introduction
10.12.4 Urolead Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
10.12.5 Urolead Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Patient Derived Xenograft/PDX Models Key Market Segments
Table 2. Key Players Covered: Ranking by Patient Derived Xenograft/PDX Models Revenue
Table 3. Ranking of Global Top Patient Derived Xenograft/PDX Models Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Patient Derived Xenograft/PDX Models Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Gastrointestinal Tumor Models
Table 6. Key Players of Gynecological Tumor Models
Table 7. Key Players of Respiratory Tumor Models
Table 8. Key Players of Urological Tumor Models
Table 9. Key Players of Hematological Tumor Models
Table 10. Global Patient Derived Xenograft/PDX Models Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Patient Derived Xenograft/PDX Models Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Patient Derived Xenograft/PDX Models Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Patient Derived Xenograft/PDX Models Market Share by Regions (2015-2020)
Table 14. Global Patient Derived Xenograft/PDX Models Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Patient Derived Xenograft/PDX Models Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Patient Derived Xenograft/PDX Models Market Growth Strategy
Table 20. Main Points Interviewed from Key Patient Derived Xenograft/PDX Models Players
Table 21. Global Patient Derived Xenograft/PDX Models Revenue by Players (2015-2020) (Million US$)
Table 22. Global Patient Derived Xenograft/PDX Models Market Share by Players (2015-2020)
Table 23. Global Top Patient Derived Xenograft/PDX Models Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Patient Derived Xenograft/PDX Models as of 2019)
Table 24. Global Patient Derived Xenograft/PDX Models by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Patient Derived Xenograft/PDX Models Product Solution and Service
Table 27. Date of Enter into Patient Derived Xenograft/PDX Models Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020) (Million US$)
Table 30. Global Patient Derived Xenograft/PDX Models Market Size Share by Type (2015-2020)
Table 31. Global Patient Derived Xenograft/PDX Models Revenue Market Share by Type (2021-2026)
Table 32. Global Patient Derived Xenograft/PDX Models Market Size Share by Application (2015-2020)
Table 33. Global Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020) (Million US$)
Table 34. Global Patient Derived Xenograft/PDX Models Market Size Share by Application (2021-2026)
Table 35. North America Key Players Patient Derived Xenograft/PDX Models Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Patient Derived Xenograft/PDX Models Market Share (2019-2020)
Table 37. North America Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020) (Million US$)
Table 38. North America Patient Derived Xenograft/PDX Models Market Share by Type (2015-2020)
Table 39. North America Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020) (Million US$)
Table 40. North America Patient Derived Xenograft/PDX Models Market Share by Application (2015-2020)
Table 41. Europe Key Players Patient Derived Xenograft/PDX Models Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Patient Derived Xenograft/PDX Models Market Share (2019-2020)
Table 43. Europe Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Patient Derived Xenograft/PDX Models Market Share by Type (2015-2020)
Table 45. Europe Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Patient Derived Xenograft/PDX Models Market Share by Application (2015-2020)
Table 47. China Key Players Patient Derived Xenograft/PDX Models Revenue (2019-2020) (Million US$)
Table 48. China Key Players Patient Derived Xenograft/PDX Models Market Share (2019-2020)
Table 49. China Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020) (Million US$)
Table 50. China Patient Derived Xenograft/PDX Models Market Share by Type (2015-2020)
Table 51. China Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020) (Million US$)
Table 52. China Patient Derived Xenograft/PDX Models Market Share by Application (2015-2020)
Table 53. Japan Key Players Patient Derived Xenograft/PDX Models Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Patient Derived Xenograft/PDX Models Market Share (2019-2020)
Table 55. Japan Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Patient Derived Xenograft/PDX Models Market Share by Type (2015-2020)
Table 57. Japan Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Patient Derived Xenograft/PDX Models Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Patient Derived Xenograft/PDX Models Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Patient Derived Xenograft/PDX Models Market Share (2019-2020)
Table 61. Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Patient Derived Xenograft/PDX Models Market Share by Type (2015-2020)
Table 63. Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Patient Derived Xenograft/PDX Models Market Share by Application (2015-2020)
Table 65. India Key Players Patient Derived Xenograft/PDX Models Revenue (2019-2020) (Million US$)
Table 66. India Key Players Patient Derived Xenograft/PDX Models Market Share (2019-2020)
Table 67. India Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020) (Million US$)
Table 68. India Patient Derived Xenograft/PDX Models Market Share by Type (2015-2020)
Table 69. India Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020) (Million US$)
Table 70. India Patient Derived Xenograft/PDX Models Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Patient Derived Xenograft/PDX Models Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Patient Derived Xenograft/PDX Models Market Share (2019-2020)
Table 73. Central & South America Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Patient Derived Xenograft/PDX Models Market Share by Type (2015-2020)
Table 75. Central & South America Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Patient Derived Xenograft/PDX Models Market Share by Application (2015-2020)
Table 77. Crown Bioscience Company Details
Table 78. Crown Bioscience Business Overview
Table 79. Crown Bioscience Product
Table 80. Crown Bioscience Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 81. Crown Bioscience Recent Development
Table 82. The Jackson Laboratory Company Details
Table 83. The Jackson Laboratory Business Overview
Table 84. The Jackson Laboratory Product
Table 85. The Jackson Laboratory Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 86. The Jackson Laboratory Recent Development
Table 87. Champions Oncology Company Details
Table 88. Champions Oncology Business Overview
Table 89. Champions Oncology Product
Table 90. Champions Oncology Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 91. Champions Oncology Recent Development
Table 92. Charles River Laboratories Company Details
Table 93. Charles River Laboratories Business Overview
Table 94. Charles River Laboratories Product
Table 95. Charles River Laboratories Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 96. Charles River Laboratories Recent Development
Table 97. WuXi Apptec Company Details
Table 98. WuXi Apptec Business Overview
Table 99. WuXi Apptec Product
Table 100. WuXi Apptec Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 101. WuXi Apptec Recent Development
Table 102. Oncodesign Company Details
Table 103. Oncodesign Business Overview
Table 104. Oncodesign Product
Table 105. Oncodesign Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 106. Oncodesign Recent Development
Table 107. Horizon Discovery Company Details
Table 108. Horizon Discovery Business Overview
Table 109. Horizon Discovery Product
Table 110. Horizon Discovery Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 111. Horizon Discovery Recent Development
Table 112. Pharmatest Services Business Overview
Table 113. Pharmatest Services Product
Table 114. Pharmatest Services Company Details
Table 115. Pharmatest Services Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 116. Pharmatest Services Recent Development
Table 117. Hera Biolabs Company Details
Table 118. Hera Biolabs Business Overview
Table 119. Hera Biolabs Product
Table 120. Hera Biolabs Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 121. Hera Biolabs Recent Development
Table 122. EPO Berlin-Buch Company Details
Table 123. EPO Berlin-Buch Business Overview
Table 124. EPO Berlin-Buch Product
Table 125. EPO Berlin-Buch Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 126. EPO Berlin-Buch Recent Development
Table 127. Xentech Company Details
Table 128. Xentech Business Overview
Table 129. Xentech Product
Table 130. Xentech Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 131. Xentech Recent Development
Table 132. Urolead Company Details
Table 133. Urolead Business Overview
Table 134. Urolead Product
Table 135. Urolead Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020) (Million US$)
Table 136. Urolead Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Patient Derived Xenograft/PDX Models Market Share by Type: 2020 VS 2026
Figure 2. Gastrointestinal Tumor Models Features
Figure 3. Gynecological Tumor Models Features
Figure 4. Respiratory Tumor Models Features
Figure 5. Urological Tumor Models Features
Figure 6. Hematological Tumor Models Features
Figure 7. Global Patient Derived Xenograft/PDX Models Market Share by Application: 2020 VS 2026
Figure 8. Pre-clinical Drug Development and Basic Cancer Research Case Studies
Figure 9. Biomarker Analysis Case Studies
Figure 10. Patient Derived Xenograft/PDX Models Report Years Considered
Figure 11. Global Patient Derived Xenograft/PDX Models Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Patient Derived Xenograft/PDX Models Market Share by Regions: 2020 VS 2026
Figure 13. Global Patient Derived Xenograft/PDX Models Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Patient Derived Xenograft/PDX Models Market Share by Players in 2019
Figure 16. Global Top Patient Derived Xenograft/PDX Models Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Patient Derived Xenograft/PDX Models as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Patient Derived Xenograft/PDX Models Revenue in 2019
Figure 18. North America Patient Derived Xenograft/PDX Models Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Patient Derived Xenograft/PDX Models Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Patient Derived Xenograft/PDX Models Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Patient Derived Xenograft/PDX Models Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Patient Derived Xenograft/PDX Models Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Patient Derived Xenograft/PDX Models Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Patient Derived Xenograft/PDX Models Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
ヒト化肝臓マウスモデルの世界市場（～2026年） Market Analysis and Insights: Global Humanized Liver Mice Models Market The global Humanized Liver Mice Models market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Humanized Liver Mice Models Scope and Market Size Humanized…- マウスモデルの世界市場（～2026年） Market Analysis and Insights: Global Mice Models Market The global Mice Models market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Mice Models Scope and Market Size Mice Models market is segmented by Type, and by Applicati…
- 消化管間質腫瘍（GIST）の世界市場（～2026年） Gastrointestinal stromal tumors (GISTs) start in special cells in the wall of the gastrointestinal (GI) tract, also known as the digestive tract. Treatment of gastrointestinal stromal tumor is multidisciplinary, entailing the involvement of medical oncologists, surgeons, radiologist, as well as path…
- サービスとしてのモビリティ（MaaS）の世界市場（～2026年） Market Analysis and Insights: Global Mobility as a Service (MaaS) Market The global Mobility as a Service (MaaS) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integri…
- 腫瘍治療フィールド（TTField）の世界市場（～2026年） Tumor Treating Field (TTField) is an anticancer treatment which disrupts the tumor cells mitosis. Tumor Treating Field is a low intensity technique which disrupts the division of cells through physical interaction of molecules during mitosis in tumor cancer. North America is projected to hold larges…